14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VVOS vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin).
Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY).
Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both VVOS (36.4/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $669.3M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment82.4% of Rev ($91M)
90D Engineering Disclosures0 Published
Investor FAQ VVOS vs DCTH Key Questions & Quantitative Answers
As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both VVOS (36.4/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), VVOS cumulative revenue shifted +100.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
DCTH screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas DCTH trades at 69.0x Forward P/E, 120.2x Trailing P/E, 1.60x PEG, and 5.6x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, DCTH carries 64.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 130% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.